Table 1.

Patient characteristics

Cohort
No. of patients66
Mean age58
Tumor size (n/%)
 T1–T251 (77%)
 T3–T415 (23%)
Lymph node status (n/%)
 N025 (38%)
 N+41 (61%)
Histologic type (n/%)
 DIC58 (87%)
 Others8 (10%)
Histologic grading (n/%)
 G1–G233 (50%)
 G330 (45%)
 NA3 (4%)
Hormonal status (n/%)
 ER+47 (71%)
 ER19 (29%)
 PR+30 (45%)
 PR36 (55%)
Ki67 Index (n/%)
 <20%8 (12%)
 ≥20%57 (86%)
 NA1 (1%)
Anti-HER2 (n/%)
 Trastuzumab45 (69%)
 Dual anti-HER220 (31%)
Chemo regimen (n/%)
 Anthracylines and taxanes43 (73%)
 Taxanes12 (20%)
 Hormonal4 (7%)
pCR
 pCR27 (41%)
 No pCR37 (56%)
 NA2 (3%)
Clinical follow-up
 Median (IQR)26 (20–33)
  • NOTE: Dual anti-HER2 includes: trastuzumab + pertuzumab (n = 17), trastuzumab + lapatinib (n = 2), and trastuzumab + neratinib (n = 1).